Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Estrella Immunopharma, Inc.ESLA · Entity 7442 | Director · CEO | August 25, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Estrella Immunopharma, Inc.
Report date August 25, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 397,437 |
Reported balance
After 2026-08-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-25 · Exercise / conversion · Acquired 100,000 · Balance 397,437 F1: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II. F2: Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-10-29 | Direct | 900,000 |
Reported balance
After 2026-08-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-25 · Exercise / conversion · Acquired 100,000 · Balance 900,000 F3: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. F4: Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
F2: Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
F3: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
F4: Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 26, 2026 23:23 UTC | Estrella Immunopharma, Inc. ESLA · Entity 7442 | Exercise / conversionIncentive Stock Option · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001996255-26-000004 · primary_doc.xml · derivative · entry 2 Liu Cheng · CIK 0001996255 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 100,000 shares Expires 2034-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. F4 · price: Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security. F3 · derivative.exercise_date: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 23:23 UTC | Estrella Immunopharma, Inc. ESLA · Entity 7442 | Exercise / conversionCommon Stock, par value $0.0001 per share | 100,000 | $0.82 | $81,500.00 |
DisclosureSEC source: 0001996255-26-000004 · primary_doc.xml · nonDerivative · entry 1 Liu Cheng · CIK 0001996255 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 397,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II. F2 · balance_after: Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise. Read SEC document |
| October 30, 2024 Filed Feb 14, 2025 21:30 UTC | Estrella Immunopharma, Inc. ESLA · Entity 7442 | GrantNonstatutory Share Option · Derivative | 509,204 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001213900-25-014310 · ownership.xml · derivative · entry 2 Liu Cheng · CIK 0001996255 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,203 Underlying: Common Stock · 509,204 shares Expires 2034-10-29 F2 · kind: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024. F2 · price: The incentive share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024. F4 · derivative.exercise_date: The nonstatutory share options will vest on a schedule, with twenty-five percent (25%) of the award being immediately exercisable on the date of the grant, with the remaining seventy-five percent (75%) vesting in equal monthly installments over the subsequent thirty-six (36) months, with 1/48th of the total number of shares subject to the option vesting on each monthly anniversary of October 30, 2024. Read SEC document |
| October 30, 2024 Filed Feb 14, 2025 21:30 UTC | Estrella Immunopharma, Inc. ESLA · Entity 7442 | GrantIncentive Share Option · Derivative | 490,796 | Not disclosed Strike: $0.82 | Not disclosed |
DisclosureSEC source: 0001213900-25-014310 · ownership.xml · derivative · entry 1 Liu Cheng · CIK 0001996255 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,796 Underlying: Common Stock · 490,796 shares Expires 2034-10-29 F1 · kind: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares. F1 · price: On October 30, 2024, the Board of Directors (the "Board") of Estrella Immunopharma, Inc. (the "Company"), awarded Mr. Cheng Liu an incentive share option grant of 490,796 shares. F3 · derivative.exercise_date: On October 30, 2024, the Board of the Company awarded Mr. Liu a nonstatutory shares option grant of 509,204 shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.